Can We Predict the Development of Serious Adverse Events (saes) and Early Treatment Termination in Elderly Non-Small Cell Lung Cancer (nsclc) Patients Receiving Platinum-Based Chemotherapy?

Predicting the feasibility of platinum-based chemotherapy remains an important issue in elderly (over 70 years) patients with non-small cell lung cancer (NSCLC). The aim of this study was to identify the risk factors for the early serious adverse events (SAEs) (during cycles 1–2) in elderly receiving platinum-based chemotherapy, and to explore the clinical characteristics of patients who require early treatment termination without progressive disease (PD).